Panacea Biotec
Innovation in support of life

November 05, 2026

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol: PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Reg.: Board Meeting on November 14, 2026, to approve Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and half year ended September 30, 2026

Dear Sir / Madam,

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), this is to inform you that:

(i) the meeting of the Board of Directors of the Company is scheduled to be held on Saturday, November 14, 2026, at New Delhi, inter-alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and half-year ended September 30, 2026;

(ii) pursuant to Regulation 46(2) of the SEBI LODR Regulations, notice of the said meeting is also being uploaded on the website of the Company; and

(iii) with reference to our earlier announcement dated September 26, 2026 intimating the Closure of Trading Window pursuant to the Company's Code of Conduct for Prevention of Insider Trading framed in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the trading window of the Company shall remain closed for all Designated Persons (including their Immediate Relatives) of the Company from October 01, 2026 till November 16, 2026.

This is for your kind information and record please.

Thanking you,
Sincerely yours,
For **Panacea Biotec Limited**

ANKIT JAIN
Digitally signed by ANKIT JAIN
Date: 2026.11.05 16:01:07 +05'30'

Ankit Jain
General Manager - Legal & Company Secretary